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878Objective: To evaluate the modular sutureless Arbor TrilogyAortic Valve System (Arbor Surgical Technologies,
Irvine, Calif), designed for minimally invasive aortic valve replacement.
Methods: In a prospective multicenter study, 32 patients with severe aortic valve stenosis underwent aortic valve
replacement with the Trilogy valve between 2006 and 2008. Concomitant coronary artery bypass grafting was
performed in 6 patients. Transthoracic echocardiography was performed at baseline, at discharge, at 4 to 6
months, at 11 to 14 months, and annually thereafter.
Results: Valve implantation was successful in 30 patients. The procedure was converted to conventional
aortic valve replacement in 2 patients. Mean bypass time was 111  42 minutes, and crossclamp time was
70  23 minutes. Valve implantation took 21  7 minutes. The transvalvular gradients at discharge were
10  3 mm Hg (mean) and 20  7 mm Hg (peak), and the effective orifice area was 1.9  0.4 cm2. At 2-year
follow-up, gradients were 7  3 mm Hg (mean) and 14  4 mm Hg (peak), and the effective orifice area was
1.9  0.3 cm2. There was no intraoperative mortality: Two patients died of causes unrelated to the valve during
follow-up. One redo aortic valve replacement was performed at 22 months for prosthetic valve endocarditis.
Conclusions: Sutureless aortic valve replacement is feasible and safe with the Trilogy System. After an initial
learning curve, the modular valve design allows a more rapid and simple implantation compared with conven-
tional stented tissue valves. The simplicity may also facilitate a greater adoption of minimally invasive aortic
valve replacement by a broader spectrum of surgeons. (J Thorac Cardiovasc Surg 2010;140:878-84)Supplemental material is available online.
The current treatment of choice for severe aortic valve steno-
sis remains valve replacement using biological or mechani-
cal valves, which are hand sewn to the aortic annulus with
a series of stitches.1 As minimally invasive techniques
have become more popular, there is a growing demand for
a prosthesis that can be easily implanted via minimal access
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The Journal of Thoracic and Cardiovascular Surgical or transfemoral devices that are available only for
high-risk patients, minimally invasive access aortic valve
replacement (AVR) using standardized sutureless valve
implantation techniques can be applied in a greater variety
of patients. With the advantages of minimally invasive ac-
cess AVR, such as improved cosmesis, less postoperative
pain, reduced risk of infection, shortened convalescence,
and decreased length of hospital stay, it has the potential
to evolve into the standard surgical technique for AVR.3-5
More than 40 years after the implantation of the first
sutureless valve by George Magovern, this technology is be-
comingmore important.6 In the last fewyears,manysutureless
aortic valves have been designed.7-9 The TrilogyAortic Valve
System (Arbor Surgical Technologies, Irvine, Calif) differs
from these in its modular valve technology, consisting of 2
parts: the valve crown and SecuRing (Figure 1, A). The valve
crown is a trilobal bovine pericardial valve on a nitinol frame
allowing independent leaflet suspension, which potentially
optimizes stress distribution on the leaflets and consequently
reduces leaflet calcification. This represents a modification
of currently available stented pericardial tissue valves, with
its promising and proven long-term durability.10,11
The second part of the system, the Trilogy SecuRing, is
similar to a standard sewing ring incorporating a nitinol
ring, providing a perfectly round inflow orifice from the
left ventricular outflow tract and elevating the valve crownery c October 2010
Abbreviations and Acronyms
AVR ¼ aortic valve replacement
EOA ¼ effective orifice area
TAC ¼ Trilogy Attachment Clip
TCAT ¼ Trilogy Crown Anchoring Tool
TSIT ¼ Trilogy SecuRing Insertion Tool




Sinto a high supra-annular position within the aortic root. This
allows all of the valve hardware to reside in the sinuses of
Valsalva and out of the blood flow path.
The modular design may simplify the surgical procedure
and result in a faster implantation as rapid-firing Trilogy At-
tachment Clips (TACs) affix the SecuRing into the annulus
under direct view. These TACs, in addition to the nitinol ring
incorporated in the sewing ring, are expected to provide
a safe and competent fixation of the SecuRing to the annulus.
The valve crown is then locked to the SecuRing, obviating
the need for sutures. This study presents the multicenter




After approval of their institutional ethics committee (No. 4355), 6 cen-
ters in Europe joined a pilot project to assess the Trilogy Aortic Valve Sys-
tem. Between November 2006 and November 2008, 32 patients (18 female,
mean age 71.7 6.5 years, body surface area 1.88 0.27 cm2, ejection frac-
tion 54% 6%) underwent AVR with the Trilogy System according to the
inclusion and exclusion criteria as shown in Table 1 and after they had given
informed consent. During the procedure bypass time, crossclamp time and
implantation time were recorded. Intraoperative transesophageal echocardi-
ography was performed after cardiopulmonary bypass to confirm adequate
valve performance.
Follow-up
After discharge examination, all patients were followed up at 4 to 6
months, at 11 to 14 months, and annually thereafter. The follow-up was per-
formed by an experienced cardiologist and included a clinical examination,
a New York Heart Association evaluation using a standardized question-
naire, and transthoracic echocardiography. Data were recorded in case
report forms at each site and then entered into a database by means of
double-data entry. Queries were generated for any discrepancies. Half-
year monitor visits took place at each site to control case report forms.
Monitor visits were performed by independent clinical research organiza-
tion (Medpass International, Paris, France).
Echocardiography
All echocardiograms were performed according to the recommendations
of the American Society of Echocardiography.12 Three beats were measured
for each variable. Mean and peak gradient were measured according to the
recommendations for quantification of Doppler echocardiography from the
American Society of Echocardiography, and effective orifice area (EOA)
was measured using the continuity equation.13 Whenever more than trivial
aortic insufficiency was found by Doppler, the severity was assessed using
(1) the width of the regurgitant jet in the left ventricular outflow tract relative
to the left ventricular outflow diameter; (2) the pressure half-time of theThe Journal of Thoracic and Caregurgitant jet recorded with the continuous-wave Doppler; and (3) the mag-
nitude and duration of the retrograde diastolic velocity in the upper descend-
ing aorta with pulse-wave Doppler according to the guidelines.12,13
All echocardiographic measurements were confirmed by an independent
core echocardiography laboratory (Cardiovascular Imaging and Clinical
Research Core Laboratory, Washington University School of Medicine,
St Louis, Mo). The core laboratory had information of the implantation
date and the implanted valve size and was blinded to other clinical data.
Experienced cardiologists who had extensive echocardiography experi-
ence performed the echogardiograms at each site. All echocardiograms
(baseline and follow-up) were performed by the same person. The echocar-
diographers had to complete an echocardiography certification process
before the enrollment of their first study patient. The certification entitled
each echocardiographer to perform 3 test echocardiograms according to
core laboratory protocol specifications. Echocardiographers were allowed
to perform echocardiography on study patients only if they met the protocol
requirements. The core laboratory judged the quality of the performed
echocardiograms. Those examinations found to be inadequate required
completion of a repeat echocardiogram within the fixed time frame.
Statistical Analysis
All data are reported as mean  standard deviation. Additional data
ranges are reported for the echocardiographic results.
Operative Technique
After median sternotomy, cardiopulmonary bypass, and cardioplegic ar-
rest, a transverse or oblique aortotomy 2 cm above the sinotubular junction
was performed. After confirmation of the tricuspid nature of the valve, the
leaflets were excised and the annulus was debrided. The annular size was
assessed using the Arbor sizer, of which one end is cylindric corresponding
to the annular diameters of 21 or 23 mm. The opposite side of the tool has
a replica of the overall Arbor Trilobal-shaped valve to allow the surgeon to
verify fit without obstructing the coronary ostia before implantation. After
sizing, the SecuRing is first mounted onto the Trilogy SecuRing Insertion
Tool (TSIT) (Figure 1, B). The prongs of the TSIT are aligned with the slots
in the SecuRing gasket package, and then the gasket is folded in a clover
shape by closing the TSIT handle. Then, the SecuRing is inserted into the
aortic root and the 3 highest points of the ring are aligned with the native
commissures. The depth of the gasket in the aortic root is adjusted using
depth markers in the TSIT. With the release button on the TSIT, the gasket
is delivered. Proper fitting into the annulus is visually confirmed using
a dental mirror before permanent attachment with the TACs begins. These
specialized clips made of superelastic Nitinol are crossed U-shape with
a length of 3.3 mm, width of 7.6 mm, and diameter of 0.4 mm (Figure 1,
C). They are stored in their unstressed parent shape in the TAC Tool
(Figure 1, C). When loaded into the air-powered TAC Tool by stepping
on a foot pedal, the TACs are spread in a ‘‘U’’ shape for insertion into an-
nular tissue. After releasing the TAC by pressing a trigger in the handle, the
TACs are driven into the SecuRing and the underlying annular tissue and the
clip legs cross over, capturing the tissue and cloth. For optimal fixation,
12 TACs usually were used (1 for each commissure and 3 for each cusp).
If necessary, the surgeon used 1 or 2 additional TACs.
In the meantime, the valve crown is prepared for implantation by rinsing
for 3 minutes in physiologic saline to remove the glutaraldehyde-based stor-
age solution. The valve crown is designed to lock into the implanted Secu-
Ring. The SecuRing commissures have guiding rails pre-sewn onto them.
There are corresponding receptacles for the rails on the outside rim of the
valve crown. During implantation, the valve crown is attached to the Trilogy
Crown Anchoring Tool (TCAT) (Figure 1,D). The rails from the gasket are
inserted through the receptacles of the valve crown, and the valve is guided
through the shield for proper placement onto the SecuRing. There is a spe-
cialized portion of the guiding rail that mechanically locks when engaging
the crown receptacles. The TCAT secures the rails during implantation and
then cuts and removes the rails, crown cap, and shield after crownrdiovascular Surgery c Volume 140, Number 4 879
FIGURE 1. A, Survey of the Trilogy Aortic Valve System (Arbor Surgical Technologies, Irvine, Calif). After affixing the SecuRing (1) with the TACs (2) to
the aortic annulus, the valve crown (3) is locked to the SecuRing using a guiding and locking mechanism (4). B, SecuRing (1) mounted onto the TSIT (2) after
folding by closing the TSIT handle. C, TAC tool (1) and TACs in their unstressed parent shape (2). When loaded into the tool, TACs are U-shaped (3) for
insertion into annular tissue. After release, the clip legs cross over in the parent shape, capturing the tissue and cloth (4). D, TCAT (1) with the inserted rails (2)
from the SecuRing guided through the valve crown and affixed on the receptacles of the TCAT (3).




Sdeployment is complete. After implantation, the aortotomy is closed in the
regular fashion. Correct positioning of the valve without paravalvular leak-
age is assessed intraoperatively using transesophageal echocardiography.RESULTS
AVR was performed using the Trilogy Aortic Valve Sys-
tem in 32 patients, 11 of whom received the 21-mm valve
and 21 of whom received the 23-mm valve. Concomitant880 The Journal of Thoracic and Cardiovascular Surgcoronary artery bypass grafting was performed in 6 patients.
There were no intraoperative deaths. Valve implantation was
successful in 30 patients. The valve had to be explanted in-
traoperatively in 2 patients. The SecuRing design was not
versatile enough to effectively seal to the valve crown in 1
patient, and a severe leakage between the gasket and the
crown was detected on intraoperative echocardiography. In
the other patient, shield manipulation caused damage toery c October 2010
TABLE 1. Inclusion and exclusion criteria
Inclusion Patient must be aged  18 y.
Patient required AVR with or without concomitant
surgical procedure, except other valve replacements.
Patient is a candidate for bioprosthetic heart valve.
Patient signed an approved informed consent form before
enrollment.
Exclusion Congenital bileaflet aortic valve.
Patient requires concomitant valve surgery.
Any disease with a poor 2-y prognosis that may interfere
with the ability to conduct follow-up.
Valve replacement on an emergency basis that does not
permit performance of the complete preoperative
evaluation.
Acute neurologic deficit, myocardial infarction, or
cardiac event within 30 d before surgery.
Renal dialysis.
Acute fungal or bacterial endocarditis.
Any abnormality, such as aortic aneurysm, that might put
the patient at high risk for surgical complications.
Pregnancy or nursing.
Documented history of substance abuse within 1 y.
Currently participating in another study of an unapproved
device or drug.
Breitenbach et al Evolving Technology/Basic Sciencethe rails and prevented crown locking. In both patients, the
valve was explanted and the procedure was converted to
conventional AVR. The patients had an uneventful postop-
erative course.
The mean bypass time in the remaining 30 patients
was 111  42 minutes, the crossclamp time was 70  23
minutes, and the implantation time was 21  7 minutes. InTABLE 2. Echocardiographic data
Time interval Valve size Mean gradient Peak gradie
Discharge 21 mm (n ¼ 10) 10  3 mm Hg 21  8 mm H
(7–14 mm Hg) (12–33 mm H
23 mm (n ¼ 19) 10  4 mm Hg 19  6 mm H
(5–22 mm Hg) (9–35 mm Hg
3–6 mo 21 mm (n ¼ 10) 11  6 mm Hg 21  8 mm H
(4–24 mm Hg) (8–35 mm Hg
23 mm (n ¼ 19) 8  4 mm Hg 15  7 mm H
(4–16 mm Hg) (7–31 mm Hg
11–14 mo 21 mm (n ¼ 8) 10  4 mm Hg 17  6 mm H
(6–13 mm Hg) (9–25 mm Hg
23 mm (n ¼ 19) 9  4 mm Hg 16  6 mm H
(5–18 mm Hg) (9–30 mm Hg
2 y 21 mm (n ¼ 1) 5 mm Hg 10 mm Hg
23 mm (n ¼ 11) 8  3 mm Hg 14  5 mm H
(4–10 mm Hg) (7–18 mm Hg
EOA, Effective orifice area; iv, intravalvular (between the SecuRing and the valve crown); LV
ranges are reported in parentheses.
The Journal of Thoracic and Cathe last 3 patients, implantation time could be reduced to
10  1 minutes.
Detailed echocardiographic results are shown in Table 2.
At discharge, regurgitation between the SecuRing and the
gasket (intravalvular) was detected in 4 patients (n¼ 2 mod-
erate, n¼ 1 mild, n¼ 1 trivial). Trivial central regurgitation
was found in 1 patient. One patient died of pulmonary
embolism confirmed by computed tomography scan. As
a result, discharge examination could be completed in
29 patients.
At the 3- to 6-month visit, 29 patients were examined. One
of the moderate intravalvular regurgitations was reduced to
mild regurgitation, and one disappeared. The cases of trivial
and mild regurgitation were still present.
At the 11- to 14-month follow-up, 27 patients were exam-
ined. Two patients were lost to follow-up. The patient with
the regurgitation at 3 to 6 months showed no more regurgi-
tation. The other intravalvular regurgitations were still
present.
At the 2-year follow-up, 12 of the expected 27 patients
were examined until now. The intravalvular regurgitation
present in patients at the 1-year follow-up was not detected
at the 2-year follow-up. Trivial central regurgitation was still
present in 1 patient. The New York Heart Association class
improved over the follow-up period (Figure 2).
During the follow-up period, 1 patient died of lung cancer.
One patient was referred back to the hospital after 22 months
because of pyrexia and dyspnea. Echocardiography showed
a vegetation of 1.5 cm at the noncoronary cusp with abscess
formation below the SecuRing. Re-do surgery was
performed. Prosthetic valve endocarditis was confirmednt EOA LVOT diameter Aortic regurgitation
g 1.8  0.3 cm2 1.8  0.2 cm –
g) (1.5–1.9 cm2) (1.6–1.9 cm)
g 2.0  0.3 cm2 1.9  0.1 cm n ¼ 2 moderate iv
) (1.5–2.6 cm2) (1.8–1.9 cm) n ¼ 1 mild iv
n ¼ 1 trivial iv
n ¼ 1 trivial central
g 1.9  0.2 cm2 1.7  0.1 cm –
) (1.7–2.1 cm2) (1.6–1.7 cm)
g 2.0  0.3 cm2 1.8  0.1 cm n ¼ 2 mild iv
) (1.5–2.4 cm2) (1.6–1.8 cm) n ¼ 1 trivial iv
n ¼ 1 trivial central
g 1.9  0.3 cm2 1.7  0.1 cm –
) (1.6–2 cm2) (1.7–1.8 cm)
g 2.1  0.3 cm2 1.8  0.1 cm n ¼ 1 mild iv
) (1.6–2.6 cm2) (1.8–2.0 cm) n ¼ 1 trivial iv
n ¼ 1 trivial central
1.8 cm2 1.7 cm –
g 2.0  0.4 cm2 1.9  0.1 cm n ¼ 1 trivial central
) (1.6–2.4 cm2) (1.8–1.9 cm)
OT, left ventricular outflow tract. Data are reported as mean standard deviation. Data





FIGURE 2. New York Heart Association class improvement over the follow-up period. NYHA, New York Heart Association.




Sintraoperatively. In addition to the vegetation, a small ab-
scess formation was detected below the SecuRing. The valve
crown was removed, and the TACs were removed using
a forceps. The SecuRing was incorporated into the annular
tissue; nevertheless, a dissection plane was found and it
was removed with no more difficulties. After aggressive de-
bridement, redo-AVR using an aortic homograft was per-
formed successfully. The patient had an uneventful
postoperative course.
Redesign of the SecuRing
Because of the severe intravalvular leakages that were de-
tected intraoperatively, resulting in a conversion to conven-
tional AVR, and the occurrence of initial intravalvular
regurgitation, the SecuRing was redesigned adding a collarFIGURE 3. A, Original SecuRing. B, Redesigned SecuRing with the additional
regurgitation.
882 The Journal of Thoracic and Cardiovascular Surgthat perfectly seals the SecuRing to the valve crown
(Figure 3). After implanting the valve using the redesigned
SecuRing (n ¼ 19), no more intravalvular regurgitation
could be detected.
DISCUSSION
AVR with biological or mechanical prostheses using the
median sternotomy as conventional access is still the gold
standard for treatment of severe aortic stenosis.1 In the past
few years, minimally invasive techniques found their way
into cardiac surgery because of their many advantages. For
high-risk patients, avoiding sternotomy by using lateral right
minithoracotomy results in early postoperative extubation,
less pain, and rapid mobilization after operation and there-
fore shortens the time to return to normal activities.14-16 Incollar (1) to seal the SecuRing to the valve crown and prevent intravalvular
ery c October 2010




Saddition, improved cosmesis and lower infection rates made
the access attractive to many patients.14-16
When using standard biological or mechanical valves, the
prostheses are hand sewn into the annulus with many
stitches. Minimally invasive approaches limit the view of
the surgeon and the operative field. As a result, the surgeon
requires more refined surgical abilities to accomplish the
same quality compared with the conventional procedure.4
Sutureless valves may simplify these techniques and facili-
tate the adoption of minimally invasive approaches by
a broader spectrum of surgeons.
Although many efforts have been taken in this field, only
2 biological valves in addition to the Trilogy Valve System
found their way into clinical practice, whereas many other
valves remained in preclinical testing.1,7-9
The 3F-Enable valve (ATS Medical, Minneapolis, Minn)
is constructed from a self-expandable nitinol-based stent
with an equine pericardial trileaflet valve sewn within the
stent,8 and the Perceval-S valve (Sorin, Milan, Italy) has
a functional component of bovine pericardium fixed in
ametal cage in a superelastic alloy of nitinol, allowing the de-
vice to be compressed and subsequently released in the annu-
lus.9 The Trilogy Valve System has a modular configuration,
enabling the surgeon to perform the entire procedure under
direct view, and all surgical manipulations are performed ex-
tracorporeally using special equipment (TCAT and TSIT).
Compared with other sutureless valves, the Trilogy valve
has a large EOA, even at 21- and 23-mm valve sizes, because
of its sinusoidal shape and modular design allowing high
supra-annular implantation (Figure E1). Compared with
the Perceval-S valve, the EOA of the Trilogy valve was
larger. Shrestha and coworkers9 reported an EOA of 1.3
(1–1.7) cm2, resulting in mean gradients of 18 (10–25)
mm Hg and peak gradients of 25 (14–35) mmHg at 1 month
in a mixed collective in which 9 patients obtained a 23-mm
Perceval-S valve and 6 patients received a 21-mm Perceval-
S valve. Compared with these series, the Trilogy valve
showed an EOA of 1.9  0.2 cm2 with mean gradients of
11  6 mm Hg and peak gradients of 21  8 mm Hg at
3 to 6 months follow-up. The 23-mm valves are even better,
with an EOA of 2.0 0.3 cm2, a mean gradient of 8 4 mm
Hg, and a peak gradient of 15  7 mm Hg.
The hemodynamic performance of the 3F-Enable bio-
prosthesis lags behind that of the Trilogy valve. Martens
and coworkers8 reported an EOA of 1.4  0.3 cm2
for the 21-mm valve, resulting in mean gradients of
10  3 mm Hg at 6 months (EOA for the 23 mm valve of
1.9 0.4 cm2 resulting in mean gradients of 11 2mmHg).
In using the Trilogy valve, we expect a positive impact of
the obtained lower gradients and the larger EOA on long-
term survival and valve durability, as reported by other
groups.17
The initial implantation series showed 4 cases of intra-
valvular regurgitation between the SecuRing and the valveThe Journal of Thoracic and Cacrown. This regurgitation completely disappeared during
the follow-up period. This may be attributed to the progre-
dient epithelialization of the valve components, especially
the SecuRing and the incorporation into the annular tissue.
Nevertheless, after the initial implantation series, the Secu-
Ring was redesigned to avoid early intravalvular regurgita-
tion. After the changes, the intravalvular regurgitation was
effectively avoided, and no regurgitation was detected in
the following 19 patients. The implantation time of the Tril-
ogy Aortic Valve System was 21  7 minutes. However,
a detailed analysis of the implantation times showed that
after a learning curve, the initial implantation time of
25 minutes was reduced to 9 to 11 minutes. These learning
curves are similar to these of other novel implantation tech-
niques.7-9 To shorten this initial learning curve, we used the
median sternotomy as access in these initial series. In the
future, we are planning the implantation of the Trilogy
Aortic Valve System via a right lateral minithoracotomy
and port access or a partial upper sternotomy to increase
the benefit for the patients and to reduce blood loss.18,19CONCLUSIONS
AVR using the Trilogy Aortic Valve System is feasible
and safe. We expect a simpler and faster implantation if
used in minimally invasive AVR. The extreme supra-
annular implantation leads to a favorable hemodynamic per-
formance. At early follow-up, it remains unclear whether
long-term durability will be better than currently available
stented pericardial tissue valves.References
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DrNawwar Al-Attar (Paris, France). In the conclusion of your
talk you described a faster implantation time, but when you showed
us the crossclamping times, they had an average of 71 minutes.
Does this compare favorably with what you do with conventional
AVR or do you really see a gain in time?884 The Journal of Thoracic and Cardiovascular SurgDr Breitenbach. If you had a closer look at our results, you
would see that we performed concomitant coronary artery bypass
grafting in 6 patients; this explains the higher crossclamping time.
Dr Al-Attar. What would be the average crossclamping time
then of a standard conventional AVR versus your new technique,
this new valve?
Dr Breitenbach. I think conventional AVR crossclamping time
ranges from 40 to 50 minutes, depending on the experience of the
surgeon. With this new technique, we could reduce the crossclamp-
ing time by 10 to 15 minutes.
Dr Al-Attar. Crossclamping time?
Dr Breitenbach. Yes, crossclamping time.
Dr Bryan Fitch Meyers (St Louis, Mo). I am always interested
in the downstream consequences of these novel techniques, and
you had to remove 2 of these valves, but you did them immediately,
apparently, in the same operation. Do you have any experience on
what it would be like to remove one of these valves after it is fully
healed in or does that change the nature of a redo operation based on
the securing system that is involved?
Dr Breitenbach. It was very easy to explant this valve because
the TACs could be easily removed without any difficulties by using
a forceps and you don’t need to cut and remove any kind of knotted
sutures as in conventional AVR.
DrMeyers.With an immediate removal, but once it is healed in,
have you removed any 3 or 6 months later?
Dr Breitenbach.We had to remove 1 valve because of endocar-
ditis at 22 months, and we did that without any difficulties.
Dr Wolfgang Harringer (Braunschweig, Germany). I have
been the principal investigator of this multicenter trial. Just a brief
comment on the last question. The animal studies in which we per-
formed chronic implantation and removal of the valve demon-
strated that it is extremely easy to take the valve out because
there is a clear dissection plane.ery c October 2010
FIGURE E1. Anatomic position of the Trilogy Aortic Valve System showing the high supra-annular position of the valve crown within the aortic root.
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